Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. China Resources Pharmaceutical Group's Marketable Securities for the quarter that ended in Dec. 2025 was €1,463 Mil.
China Resources Pharmaceutical Group's annual Marketable Securities
declined
from Dec. 2023 (€4,446 Mil) to Dec. 2024 (€1,210 Mil) but then
increased
from Dec. 2024 (€1,210 Mil) to Dec. 2025 (€1,463 Mil).
China Resources Pharmaceutical Group (STU:640) Marketable Securities Explanation
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
China Resources Pharmaceutical Group Marketable Securities Related Terms
China Resources Pharmaceutical Group Marketable Securities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group Marketable Securities Chart
What does a Marketable Securities of €1,463 Mil mean?
China Resources Pharmaceutical Group (STU:640) has a Marketable Securities of €1,463 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on China Resources Pharmaceutical Group and its competitors.
Is China Resources Pharmaceutical Group's Marketable Securities too high?
China Resources Pharmaceutical Group's current Marketable Securities is €1,463 Mil. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's Marketable Securities compare to ZTS and UTHR?
China Resources Pharmaceutical Group's Marketable Securities of €1,463 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on China Resources Pharmaceutical Group and its competitors. China Resources Pharmaceutical Group's current Marketable Securities is €1,463 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.65, compared to a current price of €0.52 — trading 20% below its estimated fair value. The current Marketable Securities is €1,463 Mil. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current Marketable Securities is €1,463 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.52 is trading 20% below its estimated GF Value™ of €0.65.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
Marketable Securities: €1,463 Mil
GF Value™: €0.65 vs. price of €0.52 (20% below fair value)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score
Get the complete analysis for STU:640
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
